Yahoo Finance3d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis (UC). This study was designed to assess the safety, tolerability, and effectiveness of PL8177 when ...
Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01
Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...
Queen Mary University of London4y
Professor Li Chan
Her work on the melanocortin receptor accessory proteins MRAP and MRAP2 as regulators of the melanocortin receptor family has revealed important novel aspects of melanocortin receptor biology. During ...
Yahoo Finance3d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated ...